Authors

• Samuel T. Wilkinson (ORCID: https://orcid.org/0000-0002-3483-9168)
• Jong‐Woo Paik (ORCID: https://orcid.org/0000-0002-1804-8497)
• Wayne C. Drevets (ORCID: https://orcid.org/0000-0002-5097-3930)
• Randall L. Morrison
• Gerard Sanacora (ORCID: https://orcid.org/0000-0003-3722-8829)
• Dong‐Jing Fu (ORCID: https://orcid.org/0000-0001-6829-0743)
• Acioly L.T. Lacerda (ORCID: https://orcid.org/0000-0002-9370-0449)
• Teodora Doherty
• Li Chen (ORCID: https://orcid.org/0000-0001-7670-8062)
• Vanina Popova (ORCID: https://orcid.org/0000-0002-9687-2238)
• Rosanne Lane
• Naim Zaki
• Allan H Young

Institutions

• Johnson & Johnson (United States) (US)
• Janssen (Belgium) (BE)
• King's College London (GB)
• Yale University (US)
• Kyung Hee University (KR)
• Janssen (United States) (US)
• Johnson & Johnson (Brazil) (BR)
• Universidade Federal de São Paulo (BR)

Publication Details

Journal

The International Journal of Neuropsychopharmacology

Published

2025-05-04

DOI

https://doi.org/10.1093/ijnp/pyaf027

Citations

21

Primary Topic

Treatment of Major Depression

Type

article

Field-Weighted Citation Impact

29.28

Funders

• Bristol-Myers Squibb
• Biogen
• Douglas Pharmaceuticals
• Usona Institute
• European College of Neuropsychopharmacology
• Janssen Research and Development
• Daiichi Sankyo Europe